Competition is heating up in the RSV space, despite a lukewarm quarter for vaccine uptake.
Pfizer beat GSK’s Arexvy for the first time in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.